RxDoctor Payments Data

Brent Coil, MD

Family Medicine · Nashville, TNNPI 1063458255

Payments from drug & device makers

$483in general payments, 2019–2025

Across 15 payments — averaging $32.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$209
  • Lilly USA, LLC$117
  • Hologic Sales And Service, LLC$46
  • Insulet Corporation$23
  • GSK$22
  • Kyowa Kirin, Inc.$20
  • plus $45 from 3 others

What the payments were for

  • Food & beverage$483100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$483 in reported general payments places this provider in the 45th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$51,732
Medicare patients
186
Services billed
922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide134$212,101
JardianceEmpagliflozin43$63,558
RybelsusSemaglutide42$62,554
MounjaroTirzepatide56$58,108
FarxigaDapagliflozin Propanediol38$42,617
XareltoRivaroxaban32$41,866
JanuviaSitagliptin Phosphate30$37,680
TrulicityDulaglutide19$29,983
KerendiaFinerenone30$27,499
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$25,255
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr33$24,838
Nurtec OdtRimegepant Sulfate23$23,733
Tresiba Flextouch U-100Insulin Degludec27$19,192
EliquisApixaban15$17,119
Stiolto RespimatTiotropium Br/Olodaterol Hcl22$12,709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$209$274,655176 claims
Lilly USA, LLCMounjaro, Trulicity$117$88,09175 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta$16$85,14181 claims
Johnson & JohnsonXarelto$12$41,86632 claims
GSKAnoro Ellipta, Breo Ellipta, Arnuity Ellipta$22$36,93960 claims
BayerKerendia$16$27,49930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →